These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
22. Phase III Multinational, Randomized, Double-Blind, Placebo-Controlled Study of Tivantinib (ARQ 197) Plus Erlotinib Versus Erlotinib Alone in Previously Treated Patients With Locally Advanced or Metastatic Nonsquamous Non-Small-Cell Lung Cancer. Scagliotti G; von Pawel J; Novello S; Ramlau R; Favaretto A; Barlesi F; Akerley W; Orlov S; Santoro A; Spigel D; Hirsh V; Shepherd FA; Sequist LV; Sandler A; Ross JS; Wang Q; von Roemeling R; Shuster D; Schwartz B J Clin Oncol; 2015 Aug; 33(24):2667-74. PubMed ID: 26169611 [TBL] [Abstract][Full Text] [Related]
23. Therapeutic Effects of Repurposed Therapies in Non-Small Cell Lung Cancer: What Is Old Is New Again. Saxena A; Becker D; Preeshagul I; Lee K; Katz E; Levy B Oncologist; 2015 Aug; 20(8):934-45. PubMed ID: 26156329 [TBL] [Abstract][Full Text] [Related]
24. Multitrial Evaluation of Progression-Free Survival as a Surrogate End Point for Overall Survival in First-Line Extensive-Stage Small-Cell Lung Cancer. Foster NR; Renfro LA; Schild SE; Redman MW; Wang XF; Dahlberg SE; Ding K; Bradbury PA; Ramalingam SS; Gandara DR; Shibata T; Saijo N; Vokes EE; Adjei AA; Mandrekar SJ J Thorac Oncol; 2015 Jul; 10(7):1099-106. PubMed ID: 26134227 [TBL] [Abstract][Full Text] [Related]
25. Non-Small-Cell Lung Cancer: Role of the Immune System and Potential for Immunotherapy. Carbone DP; Gandara DR; Antonia SJ; Zielinski C; Paz-Ares L J Thorac Oncol; 2015 Jul; 10(7):974-84. PubMed ID: 26134219 [TBL] [Abstract][Full Text] [Related]
26. Phase II study of tivantinib (ARQ 197) in patients with metastatic triple-negative breast cancer. Tolaney SM; Tan S; Guo H; Barry W; Van Allen E; Wagle N; Brock J; Larrabee K; Paweletz C; Ivanova E; Janne P; Overmoyer B; Wright JJ; Shapiro GI; Winer EP; Krop IE Invest New Drugs; 2015 Oct; 33(5):1108-14. PubMed ID: 26123926 [TBL] [Abstract][Full Text] [Related]
27. [Is chemotherapy still an option in oncogene-addicted non-small cell lung cancer? No]. Girard N Bull Cancer; 2015 Jun; 102(6 Suppl 1):S96-9. PubMed ID: 26118885 [TBL] [Abstract][Full Text] [Related]
29. Update on systemic therapy of advanced non-small-cell lung cancer. Cufer T; Knez L Expert Rev Anticancer Ther; 2014 Oct; 14(10):1189-203. PubMed ID: 25098682 [TBL] [Abstract][Full Text] [Related]
30. ALK-targeted therapy in NSCLC: likely to be of benefit but not quite ready for prime time. Socinski MA Oncology (Williston Park); 2011 Jun; 25(7):601, 604, 607. PubMed ID: 21888259 [No Abstract] [Full Text] [Related]
31. [Is chemotherapy still a valid option for oncogene-addicted lung cancer? Yes]. Besse B Bull Cancer; 2015 Jun; 102(6 Suppl 1):S93-5. PubMed ID: 26118884 [TBL] [Abstract][Full Text] [Related]
32. [Targeted therapies in non-small cell lung cancer in 2014]. Leduc C; Besse B Rev Mal Respir; 2015 Feb; 32(2):182-92. PubMed ID: 25704901 [TBL] [Abstract][Full Text] [Related]